SCHEDULE 13G/A: TCG Crossover Divests Nektar Therapeutics Stake

TCG Crossover entities and Chen Yu report 0% beneficial ownership of Nektar Therapeutics, indicating a full divestment of their previously held stake.

Summary

• TCG Crossover GP II, LLC, TCG Crossover Fund II, L.P., and Chen Yu (the Reporting Persons) have filed Amendment No. 2 to their Schedule 13G.
• The filing indicates that the Reporting Persons now beneficially own 0.00 shares, representing 0% of the Common Stock of Nektar Therapeutics, Inc.
• This amendment follows an initial Schedule 13G filed on March 15, 2024, and Amendment No. 1 filed on August 14, 2025.
• The event requiring this filing occurred on September 30, 2025, with the statement signed on November 14, 2025.
• The Reporting Persons certify that the securities were not acquired or held for the purpose of changing or influencing control of Nektar Therapeutics, Inc.

Sentiment

Score: 3

Explanation: The complete divestment of a previously held stake by a significant institutional investor is generally a negative signal, indicating a potential loss of confidence or a strategic exit from the investment.

Negatives

• The Reporting Persons, TCG Crossover GP II, LLC, TCG Crossover Fund II, L.P., and Chen Yu, have reduced their beneficial ownership in Nektar Therapeutics, Inc. to 0%, indicating a complete divestment of their reportable stake.

Risks

• A significant institutional investor reducing its stake to 0% could signal a lack of confidence in the company's future prospects or current strategy, potentially leading to negative market perception and downward pressure on the stock price.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Nektar Therapeutics, Inc. or the Reporting Persons regarding the issuer's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing reflects a change in institutional ownership for Nektar Therapeutics, a biotechnology company. Such divestments by crossover funds can sometimes be interpreted by the market as a re-evaluation of the company's long-term potential or a shift in investment strategy within the biotech sector.

Stakeholder Impact

• Shareholders may perceive the complete divestment by TCG Crossover entities as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Potential investors might view this as a red flag, prompting further due diligence into the reasons behind the institutional exit.

Key Dates

Recommendation

The complete divestment of a reportable stake by a significant institutional investor like TCG Crossover entities suggests a lack of conviction in Nektar Therapeutics' future prospects. This institutional exit could signal underlying concerns or a strategic shift away from the company, which typically leads to negative market sentiment and potential share price depreciation. For existing holders, this news warrants a re-evaluation of their position, and a 'sell' recommendation is prudent to mitigate potential further losses or reallocate capital to more promising opportunities. For non-holders, this event serves as a strong cautionary signal against initiating a position.

Keywords

Nektar Therapeutics, TCG Crossover, Schedule 13G, Beneficial Ownership, Divestment, Common Stock, Institutional Investor